Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.52 |
| ▸ | CA2 | P00918 | 10/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8062225 | 0.85 | HPGD (0.66) | CA1CA2KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL13687209 | 0.84 | CA1 (0.72) | CA1CA2 | |
| SCHEMBL8065959 | 0.84 | HPGD (0.67) | CA1CA2KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL8051169 | 0.83 | KMT2A (0.59) | CA1CA2MAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL15881063 | 0.82 | CA1 (0.57) | CA1CA2MAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL21183474 | 0.80 | POLB (0.50) | CA1CA2KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL8062224 | 0.80 | CA1 (0.56) | CA1CA2KDM4EMAPT | |
| SCHEMBL8066022 | 0.79 | HSP90AA1 (0.55) | KDM4EMAPTSMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL8067660 | 0.79 | POLB (0.62) | KDM4EMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL4146849 | 0.78 | HPGD (0.68) | KDM4EMAPTMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617208-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617208-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2190814-B1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | UNIV JOHNS HOPKINS (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2504003-B1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160081951-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20150336880-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-11-26 | — | — | US | disclosed |
| US-20150336880-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-11-26 | — | — | US | disclosed |
| US-8674132-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674132-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120258965-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258965-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-10-11 | — | — | US | disclosed |
| US-8227639-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227639-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2011063400-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063339-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20090163487-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2009-06-25 | — | — | US | disclosed |
| US-20090163487-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2009-06-25 | — | — | US | disclosed |
| WO-2009042970-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | JOHNS HOPKINS UNIVERSITY (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081951-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | NOS2, NOS3, NOS1 | CA1 3786/4885CA2 459/4885KDM4E 931/4885 |
| US-20120258965-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | CA1 2709/4885CA2 1491/4885KDM4E 2974/4885 |
| US-20090163487-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | CA1 2709/4885CA2 1491/4885KDM4E 2974/4885 |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | NOS2, NOS3, NOS1 | CA1 3870/4885CA2 747/4885KDM4E 817/4885 |
| US-20150336880-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | CA1 2709/4885CA2 1491/4885KDM4E 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.